Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.

Abstract: A method for preparing an aliphatic polyester resin powder includes the steps of a) heat dissolving a crystalline aliphatic polyester resin in an organic solvent to obtain an aliphatic polyester resin solution; b) cooling the aliphatic polyester resin solution to precipitate a solid, thereby obtaining a solid-liquid mixture; c) optionally adding an adjuvant to the solid-liquid mixture and mixing; and d) conducting solid-liquid separation and drying to obtain an aliphatic polyester resin powder suitable for selective laser sintering. The crystalline aliphatic polyester resin powder obtained has good antioxidant property, good powder flowability, moderate size, smooth surface, suitable bulk density, and suitable dispersibility and particle size distribution. The aliphatic polyester resin powder is particularly suitable for selective laser sintering method.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: A polyethylene composition comprising an ethylene/?-olefin copolymerized linear low density polyethylene, wherein the polyethylene composition has a Mw of from 100,000 g/mol to 200,000 g/mol, a Mw/Mn of from 4.0 to 9.0, a Mz/Mw of from 4.0 to 7.0, and a Mz+1/Mw of from 4.5 to 13.5, is provided. A film formed of the polyethylene composition is also provided.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and particularly to a novel class of benzazepine ketone derivatives (I), their preparation method and their pharmaceutical uses. The compounds have glycogen phosphorylase inhibiting effect and can be used in the preparation of anti-diabetes and its complications medicaments, anti-cerebral ischemia medicaments, anti-cardiovascular diseases medicaments, blood lipid-lowering medicaments, weight-reducing medicaments, anti-atherosclerosis medicaments, medicaments for treating metabolic syndrome or anti-tumor medicaments. The present invention also relates to a preparation method of the class of compounds and pharmaceutical formulations containing the same.

Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: According to one embodiment, a glass may include from about 50 mol. % to about 70 mol. % SiO2; from about 12 mol. % to about 35 mol. % B2O3; from about 4 mol. % to about 12 mol. % Al2O3; greater than 0 mol. % and less than or equal to 1 mol. % alkali metal oxide, wherein Li2O is greater than or equal to about 20% of the alkali metal oxide; from about 0.3 mol. % to about 0.7 mol. % of Na2O or Li2O; and greater than 0 mol. % and less than 12 mol. % of total divalent oxide, wherein the total divalent oxide includes at least one of CaO, MgO and SrO, and wherein a ratio of Li2O (mol. %) to (Li2O (mol. %) +(Na2O (mol. %)) is greater than or equal 0.4 and less than or equal to 0.6. The glass may have a relatively low high temperature resistivity and a relatively high low temperature resistivity.

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C?O, —SO2—, etc.; A? is selected from the group consisting of a bond, C?O, etc.; Z is —(CH2)h— or a bond, etc.; R1 and R1? are independently selected from the group consisting of hydrogen, alkyl, etc.; R2 is selected from hydrogen, alkyl, etc.; R3 is selected from the group consisting of hydrogen, and amino; R4 is monocyclic or bicyclic, etc.; R5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

Abstract: A system and method for designing a helmet to reduce mild traumatic brain injury sustained by a user during primary or secondary head impact include modeling a helmeted head including a head, brain, and helmet using a finite element computer model, the finite element computer model including material properties for the head, brain structures, and helmet and estimating at least intracranial pressure, brain strain and strain rate in response to an impact; and selecting at least one of a helmet cushion material and helmet shell material to limit at least one of intracranial pressure, brain strain and strain rate to a corresponding threshold for an associated impact.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and particularly to a novel class of benzazepine ketone derivatives (I), their preparation method and their pharmaceutical uses. The compounds have glycogen phosphorylase inhibiting effect and can be used in the preparation of anti-diabetes and its complications medicaments, anti-cerebral ischemia medicaments, anti-cardiovascular diseases medicaments, blood lipid-lowering medicaments, weight-reducing medicaments, anti-atherosclerosis medicaments, medicaments for treating metabolic syndrome or anti-tumor medicaments. The present invention also relates to a preparation method of the class of compounds and pharmaceutical formulations containing the same.

Abstract: A polyethylene composition comprising an ethylene/?-olefin copolymerized linear low density polyethylene, wherein the polyethylene composition has a Mw of from 100,000 g/mol to 200,000 g/mol, a Mw/Mn of from 4.0 to 9.0, a Mz/Mw of from 4.0 to 7.0, and a Mz+1/Mw of from 4.5 to 13.5, is provided. A film formed of the polyethylene composition is also provided.

Abstract: The present invention relates to a propylene-butene-1 random copolymer which has a butene-1 content of 1-6 mol % and a relative dispersity of butene-1, as determined according to NMR method, of greater than 98.5%. The propylene-butene-1 random copolymer of the present invention has a high relative dispersity of butene-1, as well as better transparency and heat resistance, so that it is more suitable for packaging food that may be edible after heating. Moreover, the copolymer has a lower xylene solubles content at room temperature. In addition, the present invention further relates to a method for preparing the copolymer and to a composition and an article comprising the copolymer.

Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).